All In MedTech

Device Trial Radar · NCT07059962

Sensor-based Congestion ALert for Events in Peritoneal Dialysis (SCALE-PD)

Sensor-based Congestion Alert for Events in Peritoneal Dialysis (SCALE-PD)

Last checked: Nov 20, 2026Latest source record: Oct 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

125

Planned (sponsor's estimate)

Start

Sep 9, 2025

Primary completion

Nov 2027

Study completion Nov 2027

Sponsor

Lead sponsor
Bodyport Inc.Not on our public-company list
Sponsor type
Industry
First posted
Jul 11, 2025

More device trials from this sponsor

Design

Study type
Observational
FDA-regulated device
Yes
Who can join
All sexes, from 21 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To explore the use of the Bodyport Cardiac Scale in predicting worsening of events due to fluid overload in patients with kidney disease on peritoneal dialysis.

Conditions

  • Kidney Disease
  • Peritoneal Dialysis (PD)
  • End Stage Kidney Disease (ESRD)

Interventions

  • Bodyport Cardiac ScaleDevice

    The Bodyport Cardiac Scale captures several physiological signals, which are used to derive multiple biomarkers that reflect a user's hemodynamic and fluid status.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Sensitivity AnalysisTime frame: 1 year

Locations

7 sites in 2 countries. Site status is shown where the registry gives one.

  • Desert Cities Dialysis

    Victorville, California · Recruiting

6 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.